Business Strategy
Affimed is building a mature pipeline of unique therapeutic antibodies for partnership following preclinical or clinical proof of concept studies.
Business Strategy
At Affimed, we are focused on developing innovative antibody-based therapies that improve clinical outcomes for patients with cancer and inflammatory diseases. Collaborating with leading biopharmaceutical companies is a cornerstone of Affimed´s business strategy. With our proprietary TandAb® technology, Affimed generated the next generation of therapeutic antibodies.
Affimed plans to form partnerships based on its proprietary TandAb® platform and its product portfolio. The company has access to fully human antibody libraries and, up to now has successfully generated more than twenty TandAb® antibody candidates. Our product candidates were selected against targets for which products are already on the market or in advanced clinical development, such as CD19, CD30, CD3, EpCAM, EGFR and others.
Partnering deals and strategic alliances based on our product candidates or our TandAb® technology platform comprising RECRUIT-TandAbs® and BiBLOCK-TandAbs® offer our partners a strongly competitive and versatile collaboration.